Recreational use of dextromethorphan
- For general information on this drug, including medical usage, see dextromethorphan.
Dextromethorphan (DXM), a common active ingredient found in many over-the-counter cough suppressant cold medicines, is used as a recreational drug for its dissociative effects. It has almost no psychoactive effects at medically recommended doses. Dextromethorphan has powerful dissociative properties when administered in doses well above those considered therapeutic for cough suppression. Recreational use of DXM is sometimes referred to in slang form as "robo-tripping", whose prefix derives from the Robitussin brand name, or Triple Cs, which derives from the Coricidin brand (the pills were printed with "CCC" for "Coricidin Cough and Cold").
In over the counter formulations, DXM is often combined with acetaminophen (paracetamol, APAP) to relieve pain and to prevent recreational use; however, to achieve DXM's dissociative effects, the maximum daily therapeutic dose of 4000 mg of APAP is often exceeded, potentially causing acute or chronic liver failure, making abuse and subsequent tolerance of products which contain both DXM and APAP potentially fatal.
An online essay first published in 1995 entitled "The DXM FAQ" described dextromethorphan’s potential for recreational use, and classified its effects into plateaus.
Owing to its recreational use and theft concerns, many retailers in the US have moved dextromethorphan-containing products behind the counter so that one must ask a pharmacist to receive them or be 18 years (19 in New York, Nebraska, Virginia, and Alabama, 21 in Mississippi) or older to purchase them. Some retailers also give out printed recommendations about the potential for abuse with the purchase of products containing dextromethorphan.
At high doses, dextromethorphan is classified as a dissociative general anesthetic and hallucinogen, similar to the controlled substances ketamine and phencyclidine (PCP). Also like those drugs, dextromethorphan is an NMDA receptor antagonist. Dextromethorphan generally does not produce withdrawal symptoms characteristic of physically addictive substances, but there have been cases of psychological addiction. Due to dextromethorphan's SSRI (selective serotonin re-uptake inhibitor)-like action, the sudden cessation of recreational dosing in tolerant individuals can result in mental and physical withdrawal symptoms similar to the withdrawal from SSRIs. These withdrawal effects can manifest as psychological effects, including depression, irritability, cravings, and as physical effects, including lethargy, body aches, and a sensation of unpleasant tingling, not unlike a mild "electric shock".
Dextromethorphan's effects have been divided into four plateaus. The first plateau (1.5 to 2.5 mg/kg) is described as having euphoria, auditory changes, and change in perception of gravity. The second plateau (2.5 to 7.5 mg/kg) causes intense euphoria, vivid imagination, and closed-eye hallucinations may occur. The third and fourth plateaus (600 mg, or 7.5 mg/kg and over) cause profound alterations in consciousness, and users often report out-of-body experiences or temporary psychosis. Flanging (speeding up or slowing down) of sensory input is also a characteristic effect of recreational use.
There is also a marked difference between dextromethorphan hydrobromide, contained in most cough suppressant preparations, and dextromethorphan polistirex, contained in the brand name preparation Delsym. Polistirex is a polymer that is bonded to the dextromethorphan that requires more time for the stomach to digest it as it requires that an ion exchange reaction take place prior to its dissolution into the blood. Because of this, dextromethorphan polistirex takes considerably longer to absorb, resulting in more gradual and longer lasting effects reminiscent of time release pills. As a cough suppressant, the polistirex version lasts up to 12 hours. This duration also holds true when used recreationally.
In 1981, a paper by Gosselin estimated that the lethal dose is between 50 and 500 mg/kg. Doses as high as 15–20 mg/kg are taken by some recreational users. It is suggested by a single case study that the antidote to dextromethorphan overdose is naloxone, administered intravenously.
The "DXM FAQ"
A document entitled "The DXM FAQ", by William E. White, classified dextromethorphan's high-dose effects into four or five plateaus, each defined by a dosing range. The dosages are specified in ratios of milligrams (of the drug) per kilogram (of one's body mass). According to the FAQ, the plateaus occur as follows:
- First plateau: At a dosage of 1.5 to 2.5 mg/kg, effects include alertness, restlessness, increased heartbeat, increased body temperature, intensification of emotions, euphoria, loss of balance, and slight intoxication.
- Second plateau: At 2.5 to 7.5 mg/kg, effects are similar to the first plateau, but with heavier intoxication, choppy sensory input, a dreamlike state of consciousness, some detachment from outside world, and closed-eye hallucinations.
- Third plateau: At 7.5 to 15.0 mg/kg, effects include flanging of visual effects, difficulty recognizing people or objects, chaotic blindness, dreamlike vision, inability to comprehend language, abstract hallucinations, delayed reaction time, decision making impairment, feelings of peace and quiet, near complete loss of motor coordination, short-term memory impairment, and/or feelings of rebirth.
- Fourth plateau: At 15.0 mg/kg or more, an individual may experience a perceived loss of contact and control with their own body, changes in visual perception, out-of-body experiences, perceptions of contact with "superior" beings, other miscellaneous delusions, lack of movement or desire to move, rapid heart rate, complete blindness, increased hearing, and intensification of third plateau effects.
- Plateau Sigma: 2.5–7.5 mg/kg every three hours for 9–12 hours; occurs by prolonging dosage. Plateau sigma is marked by the presence of psychosis with visual and auditory hallucinations. Users have reported that inclinations manifest as auditory hallucinations; rather than simply feeling tired and sitting down, a user might hear a voice saying, "sit down now, you're tired," and feel inclined to obey. White says that of all the reports of Plateau Sigma experiences he received, over half were described as unpleasant.
Risks associated with use
Dextromethorphan has not been shown to cause vacuolization in animals, also known as Olney's lesions, despite early speculation that it may, due to similarities with phencyclidine (PCP). In rats, oral administration of dextromethorphan did not cause vacuolization in laboratory tests. Oral administration of dextromethorphan repeatedly during adolescence, however, has been shown to impair learning in those rats during adulthood. The occurrence of Olney's lesions in humans, however, has not been proven or disproven. William E. White, author of the "DXM FAQ", has compiled informal research from correspondence with dextromethorphan users suggesting that heavy abuse may result in various deficits corresponding to the brain areas affected by Olney's lesions; these include loss of episodic memory, decline in ability to learn, abnormalities in some aspects of visual processing, and deficits of abstract language comprehension. In 2004, however, White retracted the article in which he made these claims.
A formal survey of dextromethorphan users showed that more than half of users reported experience of the following withdrawal-symptoms individually for the first week after long-term/addictive dextromethorphan use: fatigue, apathy, flashbacks, and constipation. Over a quarter reported insomnia, nightmares, anhedonia, impaired memory, attention deficit and decreased libido. Rarer side effects included panic attacks, impaired learning, tremor, jaundice, urticaria (hives) and myalgia. Frequent and long-term usage at very high doses could possibly lead to toxic psychosis and other permanent psychological problems.
Erectile dysfunction and diminished libido can be a longer-term effect (years to decades) of many narcotic analgesics due to development of central hypogonadism; this appears especially common in individuals with significant melanin deficiencies, as the hormones tied to melanin production affect the absorption and conversion of these analgesics into progesterone. Additionally, the haplotypes of about 48% of the indigenous population of Great Britain aggravate the condition, as the E647 sequence underwent epigenetic degradation and became a pseudogene. The chance of vulnerability is doubled for males, as the critical sequence is located on the X chromosome.
Misuse of multi-symptom cold medications, rather than using a cough suppressant whose sole active ingredient is dextromethorphan, carries significant risk of fatality or serious illness. Multi-symptom cold medicines contain other active ingredients, such as paracetamol (acetaminophen), chlorpheniramine, and phenylephrine, any of which can cause permanent bodily damage such as kidney failure, or even death, if taken on the generally accepted recreational dosing scale of dextromethorphan. Sorbitol, an artificial sweetener found in many cough syrups containing dextromethorphan, can also have negative side effects including diarrhea and nausea when taken at recreational dosages of dextromethorphan. Guaifenesin, an expectorant commonly accompanying dextromethorphan in cough preparations, can cause unpleasant symptoms including vomiting, nausea, and headache. Thus it is extremely important to use products which contain only DXM and no other active ingredients.
Combining dextromethorphan with other substances can compound risks. CNS stimulants such as amphetamine and/or cocaine can cause a dangerous rise in blood pressure and heart rate. CNS depressants such as ethanol (drinking alcohol) will have a combined depressant effect, which can cause a decreased respiratory rate. Combining dextromethorphan with other CYP2D6 substrates can cause both drugs to build to dangerous levels in the bloodstream.
Combining dextromethorphan with other serotonergic drugs could possibly cause serotonin toxicity, an excess of serotonergic activity in the central nervous system (CNS) and peripheral nervous system (PNS).
Dextromethorphan's hallucinogenic and dissociative effects can be attributed largely to dextrorphan (DXO), a metabolite produced when dextromethorphan is metabolized by the body. Both dextrorphan and dextromethorphan are NMDA receptor antagonists, like the dissociative hallucinogenic drugs ketamine and phencyclidine (PCP), although dextrorphan is more potent than its "parent molecule" dextromethorphan.
As with all NMDA receptor antagonists, dextrorphan and dextromethorphan inhibit the excitatory amino acid and neurotransmitter glutamate in the brain. This can effectively slow, or even shut down certain neural pathways, preventing areas of the brain from communicating with each other. This leaves the user feeling dissociated or disconnected, experienced as brain fog or derealization.
Dextromethorphan's euphoric effects have sometimes been attributed to an increase in dopamine levels, since such an increase generally correlates with pleasurable responses to drug, as is observed with some clinical antidepressants, as well as some recreational drugs. However, the effects of dextrorphan and dextromethorphan, and other NMDA receptor antagonists, on dopamine levels is a disputed subject. Studies show that the NMDA receptor antagonists ketamine and PCP do raise dopamine levels, although other studies show that another NMDA receptor antagonist dizocilpine has no effect on dopamine levels. Some findings even suggest that dextromethorphan can actually counter the dopamine-increasing effect caused by morphine. Due to these conflicting results, the actual effect of dextromethorphan on dopamine levels remain undetermined.
In Russia, dextromethorphan (commonly sold under the brand names Tussin+ and Glycodin) is a Schedule III controlled substance and is placed in the same list as benzodiazepines and the majority of barbiturates.
No legal distinction currently exists in the United States between medical and recreational use, sale, or purchase. Some states and store chains have implemented restrictions, such as requiring signatures for DXM sale, limiting quantities allowable for purchase, and requiring that purchasers be over the age of majority in their state.
The sale of dextromethorphan in its pure powder form may incur penalties, although no explicit law exists prohibiting its sale or possession, other than in the state of Illinois. There have been cases of individuals being sentenced to time in prison and other penalties for selling pure dextromethorphan in this form, because of the incidental violation of more general laws for the sale of legitimate drugs — such as resale of a medication without proper warning labels.
Dextromethorphan was excluded from the Controlled Substances Act (CSA) of 1970 and was specifically excluded from the Single Convention on Narcotic Drugs. Dextromethorphan is still excluded from the CSA (as of 2010); however, officials have warned that it could still be added if increased abuse warrants its scheduling. The motivation behind its exclusion from the CSA was that, under the CSA, all optical isomers of listed Schedule II opiates are automatically Schedule II substances. Since dextromethorphan is an optical isomer of the Schedule II opiate levomethorphan (but does not act like an opiate), an exemption was necessary to keep it a non-controlled substance. The Federal Analog Act does not apply to dextromethorphan because a new drug application has been filed for it.
Indonesia Food and Drug Monitoring Agency (BPOM) has released regulation before that on June 30, 2014 all drugs with Dextromethorphan should be pulled from the market of worrying increase misuse of 'Dextro' as recreational drugs with its hallucinogenic side effects. In Indonesia, Dextro mainly are used by elementary and high school students, because cheap price of Dextro tablets or antitussive syrups with Dextro.
- Dissociative drug
- NMDA receptor antagonist
- Purple drank
- Sigma agonist
- "Dextromethorphan (DXM) | CESAR". Cesar.umd.edu. Retrieved 14 February 2014.
- "DXM APAP". Cigna.com. Cigna Health Care. Archived from the original on 6 January 2013. Retrieved 4 Jan 2012.
- "Darkridge |The Dextromethorphan DXM FAQ". DXM.darkridge.com. Retrieved 14 February 2014.
- "DEXTROMETHORPHAN (Street Names: DXM, CCC, Triple C, Skittles, Robo, Poor Man’s PCP". Deadiversion.usdoj.gov). Archived from the original on 19 December 2010.
- "FORMER MINOTMAN AND INTERNET CHEMICAL COMPANY SENTENCED FOR SELLING DESIGNER AND MISBRANDED DRUGS AND VIOLATING FEDERAL CUSTOMS LAWS" (PDF) (Press release). Erowid. 30 June 2006. Retrieved 14 February 2014.
- "Erowid DXM Vault : Effects". Erowid. Retrieved 14 February 2014.
- "Drug Abuse Help: DXM Information". Drugabusehelp.com. Retrieved 14 February 2014.
- ":: Cough Syrup and Dextromethorphan (DXM) Addiction and Abuse – Drug Rehab Information ::". Info-drug-rehab.com. Archived from the original on 17 September 2013.
- Bornstein, S; Czermak, M; Postel, J (1968). "Apropos of a case of voluntary medicinal intoxication with dextromethorphan hydrobromide". Annales Medico-Psychologiques 1 (3): 447–451. PMID 5670018.
- Dodds, A; Revai, E (1967). "Toxic psychosis due to dextromethorphan". Med J Aust 2: 231.
- Schneider, SM; Michelson, EA (1991). "Dextromethorphan poisoning reversed by naloxone". Am. J. Emerg. Med 9 (3): 237–238. doi:10.1016/0735-6757(91)90085-X. PMID 2018593.
- "Erowid DXM Vault : Drug Tests". Erowid. Retrieved 14 February 2014.
- "Erowid DXM Vault : DXM FAQ – The Experience". Erowid. Retrieved 14 February 2014.
- Anderson, Cliff. "The Bad News Isn't In". Erowid. Retrieved 14 February 2014.
- Hashimoto, K; Tomitaka, S; Narita, N; Minabe, Y; Iyo, M; Fukui, S (1996). "Induction of heat shock protein Hsp70 in rat retrosplenial cortex following administration of dextromethorphan". Environmental Toxicology and Pharmacology 1 (4): 235–239. doi:10.1016/1382-6689(96)00016-6. PMID 21781688.
- Carliss, RD; Radovsky, A; Chengelis, CP; O'neill, TP; Shuey, DL (2007). "Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain". NeuroToxicology 28 (4): 813. doi:10.1016/j.neuro.2007.03.009. PMID 17573115.
- Zhang, TY; Cho, HJ; Lee, S; Lee, JH; Choi, SH; Ryu, V et al. (2006). "Impairments in water maze learning of aged rats that received dextromethorphan repeatedly during adolescent period". Psychopharmacology 191 (1): 171–9. doi:10.1007/s00213-006-0548-3. PMID 17021924.
- White, William E. "Erowid DXM Vault : This is your brain on dissociatives, the bad news is finally in" (TXT). Dextroverse.com. Retrieved 14 February 2014.
- White, William E. "Erowid DXM Vault : Response to "The Bad News Isn't In": Please Pass The Crow, by William E. White". Erowid. Retrieved 14 February 2014.
- Ziaee, V; Akbari Hamed, E; Hoshmand, A; Amini, H; Kebriaeizadeh, A; Saman, K (September 2005). "Side effects of dextromethorphan abuse, a case series". Addictive Behavior 30 (8): 1607–13. PMID 16122622.
- Advanced Hormone Physiology[full citation needed]
- Busch and Grenfield, et al.[full citation needed]
- Kirages, T; Sulé, H; Mycyk, M (2003). "Severe manifestations of coricidin intoxication". Am J Emerg Med 21 (6): 473–5. doi:10.1016/S0735-6757(03)00168-2. PMID 14574654.
- Kintz, P; Mangin, P (December 1992). "Toxicological findings in a death involving dextromethorphan and terfenadine". Am J Forensic Med Pathol 13 (4): 351–352. doi:10.1097/00000433-199212000-00018. PMID 1288270.
- "Erowid DXM Vault : Guide to DXM in Non-Prescription Drugs". Erowid. Retrieved 14 February 2014.
- "Drugs and Human Performance FACT SHEETS – Dextromethorphan". Nhsta.gov. National Highway Traffic Safety Administration.
- "Erowid DXM Vault : DXM FAQ – Side Effects". Erowid. Retrieved 14 February 2014.
- Helmy, SAK; Bali, A (2002). "The effect of the preemptive use of the NMDA receptor antagonist dextromethorphan on postoperative analgesic requirements". Anesthesia and Analgesia (in French/English) (Cat.Inist.fr) 92 (3): 739–744. ISSN 0003-2999.
- Pechnick, RN; Poland, RE. "Comparison of the Effects of Dextromethorphan, Dextrorphan, and Levorphanol on the Hypothalamo-Pituitary-Adrenal Axis – Pechnick and Poland". Journal of Pharmacology And Experimental Therapeutics 309 (2): 515. doi:10.1124/jpet.103.060038. PMID 14742749.
- Muir, KW; Lees, KR (1995). "Clinical experience with excitatory amino acid antagonist drugs". Stroke 26 (3): 503–513. doi:10.1161/01.STR.26.3.503. PMID 7886734.
- Kristensen, JD; Svensson, B; Gordh Jr., T (1992). "The NMDA-receptor antagonist CPP abolishes neurogenic 'wind-up pain' after intrathecal administration in humans". Pain 51 (2): 249–253. doi:10.1016/0304-3959(92)90266-E. PMID 1484720.
- Kapur, S; Seeman, P (2002). "NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2receptors implications for models of schizophrenia". Molecular Psychiatry 7 (8): 837–844. doi:10.1038/sj.mp.4001093. PMID 12232776.
- Verma, A; Moghaddam, B (16 January 1996). "NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine". Journal of Neuroscience 1 (1): 373–9. PMID 8613804.
- Steinmiller, CL; Maisonneuve, IM; Glick, SD (2003). "Effects of dextromethorphan on dopamine release in the nucleus accumbens: Interactions with morphine". Pharmacol Biochem Behav (Center for Neuropharmacology and Neuroscience (MC-136)) 74 (4): 803–10. doi:10.1016/S0091-3057(02)01080-8. PMID 12667894.
- Carrozza, DP; Ferraro, TN; Golden, GT; Reyes, PF; Hare, TA (1992). "In vivo modulation of excitatory amino acid receptors: microdialysis studies on N-methyl-D-aspartate-evoked striatal dopamine release and effects of antagonists". Brain Res 574 (1–2): 42–8. doi:10.1016/0006-8993(92)90797-D. PMID 1353403.
- Huang, EY; Liu, TC; Tao, PL (2003). "Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens". Brain Res 368 (5): 386–92. doi:10.1007/s00210-003-0803-7. PMID 14564449.
- "Erowid DXM Vault : Legal Status". Erowid. Retrieved 14 February 2014.
- "Decision of the Government of the Russian Federation No. 681 of June 30, 1998 on the Approval of the List of Narcotic Drugs, Psychotropic Substances and Their Precursors That Shall Be Subject to Control in the Russian Federation (with Amendments and Additions)". Base.garant.ru (in Russian). Retrieved 14 February 2014.
- Ainur Rohmah (June 26, 2014). "Dextro pulled after rise in recreational use".
- The Electric Cough-Syrup Acid Test by Jim Hogshire from Harper's
- Erowid Dextromethorphan Vault